Antineutrophil cytoplasmic antibody-associated vasculitis

Area of Science:

• Immunology
• Rheumatology
• Nephrology

Background:

• Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune disease causing small blood vessel inflammation.
• Pathogenesis involves autoantibodies and complement activation, with a focus on reducing glucocorticoid toxicity.

Purpose of the Study:

• To review recent advancements in managing ANCA-associated vasculitis.
• To highlight emerging therapeutic strategies and personalized management approaches.

Main Methods:

• Review of current literature on AAV management.
• Analysis of recent clinical trial data and guideline updates.

Main Results:

• Complement inhibitors (e.g., avacopan) show promise in preserving kidney function in severe AAV.
• Plasma exchange (PLEX) is recommended for specific cases of diffuse alveolar hemorrhage and severe kidney involvement.
• Risk prediction scores (ANCA Kidney Risk Score, Glucocorticoid Toxicity Index) aid in individualized patient management.

Conclusions:

• Prompt diagnosis and immunosuppression are critical for preventing kidney damage in AAV.
• Novel therapeutic targets and personalized strategies are advancing AAV treatment.